Plenty of drugmakers are chasing opportunity in diabetes. The fast-growing epidemic means new therapies are sorely needed. But dealing with diabetes directly isn't the only strategy. Regeneron figures it can score by treating some of the disease's long-term complications.
Since 2007, the wholesale cost for a one-month supply of insulin product Humulin has gone from about $220 to approximately $1,200, MedPage Today reports.
Among all the pharma companies, Novo Nordisk always stood out for its relentless R&D focus on diabetes and obesity. Today, the Danish company amped up that concentration another notch, jettisoning a group of clinical programs and winding down its work in anti-inflammatory treatments. And the pharma player added that the move would hit some 400 staffers, with close to half likely to lose their jobs at Novo.
Merck's America's Diabetes Challenge: Get to Your Goals campaign is aimed at persuading patients to do what it takes to keep their blood sugar in check. Now, Merck is launching a similar campaign aimed at the Hispanic community, which is disproportionately affected by the disease.
Scientists have linked a single enzyme to the development of diabetes, a finding that could help develop new treatments for the more than 120 million Americans that have diabetes or pre-diabetes.
Without the safety concerns that plague its competitors, Jardiance may be able to make a splash.
Investigators at The Scripps Research Institute discovered a signaling pathway that switches on a calorie-burning phenomenon in cells.
The FDA is changing its tune on Jardiance, a Boehringer Ingelheim diabetes med it hasn't been so keen on in the past. After rejecting the drug in the face of a manufacturing issue, the agency Friday gave it approval to treat Type 2 diabetes.
According to an internal memo obtained by The Wall Street Journal blog Pharmalot, Whitaker is leaving for "another opportunity."
A committee of European Medicines Agency advisers is recommending approval for Novo Nordisk's combination of a long-acting insulin and its blockbuster GLP-1 drug Victoza, setting the stage for a near-term approval of what's expected to be the diabetes giant's next big therapy.